






FOR MORE INFORMATION, PLEASE CONTACT:

Addressing specialty and non-specialty drugs

The Stealth Targeted Patient Assistance Program (PAP) is an alternate funding solution for all eligible specialty drugs covered on the health plan. Stealth/Amwins Rx identifies funding from manufacturers, philanthropic associations and other sources for high-cost Specialty and Branded medications. Our team coordinates with the existing Pharmacy Benefit Manager (PBM) to determine whether there is funding for specific drugs and works with the plan, patient and funding source to dispense the drug.

Our Targeted PAP program focuses on a single drug. This allows plans to take advantage of alternative funding sources for a specific drug without having to change their current PBM. This unique tool provides an opportunity access alternative funding sources for targeted high-cost drugs with minimal plan design changes or re-contracting.

Case studies: actual patient savings realized by Stealth/Amwins Rx clients

 Medication Name	 Reason for Use	 Plan Annual Savings
Strensiq	Hypophosphatasia	\$1.73M
Idelvion	Hemophilia	\$500,000
Tasigna	Cancer Medication	\$154,659.72
Gilenya	Multiple Sclerosis	\$118,233.24
Biktarvy	HIV	\$38,432.00

You will find value in our program through:

Targeted PAP addresses specialty and non-specialty drugs

- Reduces plan & member costs by maximizing copay assistance funds for brand name specialty and select non-specialty drugs from pharmaceutical manufacturers
- Identifies eligible members and reports savings captured and plan/member impact
- There are many non-specialty medications that can incur significant plan costs

